Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.
Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder.
Ann Med. 2019 Aug 27;:1-13
Authors: Calkin CV
Abstract
Bipolar Disorder (BD) is a major psychiatric illness affecting up to 5% of the population. BD can progress over time to a chronic "neuroprogressive" course with cognitive and functional impairment. Currently, there are no validated predictors indicating which patients will develop a neuroprogressive course and there are no specific treatments. This review presents data supporting a novel hypothesis on the mechanisms underlying bipolar neuroprogression. Insulin resistance (IR) is present in 52% of BD patients and is associated with chronic course, treatment nonresponse, adverse brain changes and cognitive impairment. Further, bipolar morbidity increases 12-fold following the onset of IR indicating that IR may modify disease progression. I review evidence that IR is a testable and treatable modifying factor in neuroprogression and that reversing IR may be an efficient (and perhaps the only) means of obtaining remission in some patients. I draw a parallel with Helicobacter pylori in peptic ulcer disease (a novel mechanism that brought together two previously unrelated phenomena that uncovered a new treatment approach). This model of bipolar progression combines shared dysregulated mechanisms between IR and BD, allowing for early screening, case finding, and monitoring for neuroprogression, ...
Source: Annals of Medicine - Category: Internal Medicine Tags: Ann Med Source Type: research
More News: Bipolar | Brain | Helicobacter Pylori | Insulin | Internal Medicine | Mania | Neurology | Peptic Ulcer | Psychiatry